$0.93
(3.16%)
Add to watchlist
Create an alert
Stocks and Shares ISATG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Company Information
About this company
Key people
Michael S. Weiss
Chairman of the Board, President, Chief Executive Officer
Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Laurence Neil Charney
Lead Independent Director
Yann Echelard
Independent Director
Kenneth Hoberman
Independent Director
Daniel Hume
Independent Director
Sagar Lonial
Independent Director
Click to see more
Key facts
- Shares in issue162.30m
- EPICTGTX
- ISINUS88322Q1085
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$4.67bn
- Employees374
- ExchangeNASDAQ
- IndexS&P 600 Small Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.